Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Patients with Multiple Sclerosis.

Background Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis (MS). The objective was to describe clinical pharmacy services provided, as well as provider satisfaction with and perceived impact of incorporating a clinical pharmacist in MS patient care. Methods The study consisted of a retrospective medical record review and a provider survey conducted in an outpatient neurology clinic at an academic medical center. Between April 2017 and June 2018, electronic medical records of patients with documented interventions by a pharmacist were reviewed to describe clinical pharmacy services provided to patients with MS. A voluntary, anonymous survey was distributed to neurology providers to evaluate provider satisfaction with and perceived impact of clinical pharmacist involvement in MS patient care. Results There were 64 patients identified with 378 documented interventions made by clinical pharmacists. Pharmacist interventions were mostly related to facilitating medication access (n = 208), pretreatment screening (n = 57), patient counseling (n = 51), and providing drug information (n = 43). All nine providers surveyed indicated that facilitating medication access, counseling patients, and managing drug interactions were moderately or very important clinical pharmacy services. Furthermore, all providers surveyed strongly agreed that pharmacist involvement decreased time to therapy initiation and provider time spent on medication management. Conclusions Clinical pharmacists play an integral role in MS patient care, particularly with facilitating medication access. Prospective studies are needed to further evaluate the contribution of clinical pharmacists in MS patient care.

• Publication year

  2020

• Venue

  International Journal of MS Care

• Publication date

  2020-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.7224/1537-2073.2019-032PMID 33658901PMCID PMC7906034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program

  2018cited by this paper
• Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

  2018cited by this paper
• Physician-reported factors that encourage collaboration with community pharmacists.

  2017cited by this paper
• A Survey of Staff Perceptions of an Emergency Medicine Pharmacist Program in a Community Hospital: A Brief Report

  2017cited by this paper
• Clinical pharmacists in primary care: Provider satisfaction and perceived impact on quality of care provided

  2017cited by this paper
• Walgreens connected care: impact of managed therapy on adherence to medications used to treat multiple sclerosis and related comorbid conditions.

  2015cited by this paper
• The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

  2015cited by this paper
• The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

  2015cited by this paper
• Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population

  2014cited by this paper
• Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis.

  2014cited by this paper
• Working-age persons with multiple sclerosis and access to disease-modifying medications

  2008cited by this paper
• Health, disability, and life insurance experiences of working-age persons with multiple sclerosis

  2007cited by this paper
• Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1352458510373487

  year unknowncited by this paper

• Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models.

  2025cites this paper
• Health-system specialty pharmacist intervention types, acceptance, and associated actions for patients with multiple sclerosis.

  2024cites this paper
• Benefit of Clinical Pharmacists in Neurology Clinics at an Academic Medical Center.

  2024cites this paper
• The Tell on Telehealth

  2024cites this paper
• Describing and Evaluating the Clinical Pharmacist's Role in a Canadian Multiple Sclerosis Clinic.

  2024cites this paper
• The Role of Clinical Pharmacists in Patient-Centric Comprehensive Multiple Sclerosis Care.

  2023cites this paper
• Patient-reported outcomes and pharmacist actions in patients with multiple sclerosis managed by health-system specialty pharmacies.

  2023cites this paper
• Integrating neurology and pharmacy through telemedicine: A novel care model

  2021cites this paper
• on Short Term Quality of

  year unknowncites this paper